MX2010001047A - Agente preventivo o agente terapéutico para enfermedades provocadas por metabolismo óseo anormal. - Google Patents
Agente preventivo o agente terapéutico para enfermedades provocadas por metabolismo óseo anormal.Info
- Publication number
- MX2010001047A MX2010001047A MX2010001047A MX2010001047A MX2010001047A MX 2010001047 A MX2010001047 A MX 2010001047A MX 2010001047 A MX2010001047 A MX 2010001047A MX 2010001047 A MX2010001047 A MX 2010001047A MX 2010001047 A MX2010001047 A MX 2010001047A
- Authority
- MX
- Mexico
- Prior art keywords
- acid
- disease caused
- bone metabolism
- abnormal bone
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se pretende proporcionar un agente preventivo o un agente terapéutico para una enfermedad provocada por metabolismo óseo anormal, en particular, osteoporosis, más efectivo que nunca. Al combinar la aplicación de N-hidroxi-4-{5-[4-(5-isopropil-2-metil-1 , 3-tiazol-4-il)fenoxi)pentoxi}-benzamidina, o sal de la misma, y uno de los compuestos seleccionados del grupo que consiste de ácido etidrónico, ácido clodrónico, ácido pamidrónico, ácido tiludrónico, ácido risedrónico, ácido minodrónico, ácido ibandrónico, ácido zoledrónico, y sales de los mismos, se muestra una acción inhibidora de resorción ósea mayor en comparación con la administración de un compuesto individual, y puede obtenerse un excelente efecto preventivo y efecto terapéutico para una enfermedad provocada por metabolismo óseo anormal, en particular, para osteoporosis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93526207P | 2007-08-02 | 2007-08-02 | |
| PCT/JP2008/063864 WO2009017222A1 (ja) | 2007-08-02 | 2008-08-01 | 骨代謝異常に起因する疾患の予防剤又は治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010001047A true MX2010001047A (es) | 2010-03-03 |
Family
ID=40304451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010001047A MX2010001047A (es) | 2007-08-02 | 2008-08-01 | Agente preventivo o agente terapéutico para enfermedades provocadas por metabolismo óseo anormal. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100216747A1 (es) |
| EP (1) | EP2177219A4 (es) |
| JP (1) | JPWO2009017222A1 (es) |
| KR (1) | KR20100045450A (es) |
| CN (1) | CN101808640A (es) |
| AU (1) | AU2008283297A1 (es) |
| CA (1) | CA2694638A1 (es) |
| MX (1) | MX2010001047A (es) |
| WO (1) | WO2009017222A1 (es) |
| ZA (1) | ZA201000739B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100014090A (ko) * | 2008-08-01 | 2010-02-10 | 동화약품주식회사 | 벤즈아미딘 유도체 또는 이의 염, 및 비스포스포네이트를 포함하는 골다공증의 예방 또는 치료용 약학 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU687744B2 (en) * | 1993-05-15 | 1998-03-05 | Riemser Arzneimittel Ag | More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent |
| US5998390A (en) * | 1998-09-28 | 1999-12-07 | The Research Foundation Of State University Of New York | Combination of bisphosphonate and tetracycline |
| KR100454767B1 (ko) | 2001-07-19 | 2004-11-03 | 동화약품공업주식회사 | 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도 |
| JP2003292453A (ja) * | 2002-04-02 | 2003-10-15 | Asahi Kasei Corp | 骨疾患治療用医薬複合剤 |
| JPWO2005002590A1 (ja) * | 2003-07-01 | 2006-08-10 | アステラス製薬株式会社 | 骨量増加誘導剤 |
-
2008
- 2008-08-01 CA CA2694638A patent/CA2694638A1/en not_active Abandoned
- 2008-08-01 KR KR1020107002120A patent/KR20100045450A/ko not_active Application Discontinuation
- 2008-08-01 US US12/671,414 patent/US20100216747A1/en not_active Abandoned
- 2008-08-01 CN CN200880109481A patent/CN101808640A/zh active Pending
- 2008-08-01 JP JP2009525459A patent/JPWO2009017222A1/ja not_active Ceased
- 2008-08-01 EP EP08792077A patent/EP2177219A4/en not_active Withdrawn
- 2008-08-01 AU AU2008283297A patent/AU2008283297A1/en not_active Abandoned
- 2008-08-01 WO PCT/JP2008/063864 patent/WO2009017222A1/ja active Application Filing
- 2008-08-01 MX MX2010001047A patent/MX2010001047A/es not_active Application Discontinuation
-
2010
- 2010-02-01 ZA ZA201000739A patent/ZA201000739B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201000739B (en) | 2010-10-27 |
| JPWO2009017222A1 (ja) | 2010-10-21 |
| KR20100045450A (ko) | 2010-05-03 |
| US20100216747A1 (en) | 2010-08-26 |
| WO2009017222A1 (ja) | 2009-02-05 |
| CN101808640A (zh) | 2010-08-18 |
| EP2177219A1 (en) | 2010-04-21 |
| AU2008283297A1 (en) | 2009-02-05 |
| CA2694638A1 (en) | 2009-02-05 |
| EP2177219A4 (en) | 2010-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013500995A5 (es) | ||
| JOP20210187A1 (ar) | تركيبات تشتمل على معدلات مستقبل سفينجوزين 1 فوسفات (s1p) | |
| Reid et al. | Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? | |
| Gutta et al. | Bisphosphonates and osteonecrosis of the jaws: science and rationale | |
| Russell | Bisphosphonates: mode of action and pharmacology | |
| JP2015518828A5 (es) | ||
| JP2009522369A5 (es) | ||
| NO20032405D0 (no) | Anvendelse av bisfosfonater ved smertebehandling | |
| CY1121703T1 (el) | Ιατρικη χρηση του πολυμορφου a toy ibanδρονικου | |
| JP2009541475A5 (ja) | ＨＭＧ−ＣｏＡ還元酵素阻害剤およびファルネシルピロリン酸合成酵素阻害剤を含む治療剤 | |
| JP2002529490A5 (es) | ||
| NZ545804A (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate | |
| CL2012001841A1 (es) | Polimorfo cristalino de la forma a de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetato de sodio; método de preparación; composición farmacéutica; y su uso para el tratamiento o prevención de hiperuricemia o una enfermedad causada por niveles elevados de ácido úrico. | |
| MX2019012750A (es) | Moduladores del receptor s1p para el tratamiento de esclerosis multiple. | |
| IL194277A (en) | Zoladronic Acid Compounds for Oral Administration | |
| JP2015500333A5 (es) | ||
| MX2009006447A (es) | Composicion farmaceutica de liberacion sostenida a largo plazo que contiene suspension acuosa de bisfosfonato. | |
| MY176246A (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease | |
| MX2015010433A (es) | Derivados de acido bisfenil-butanoico fosfonico sustituido como inhibidores de la endopeptidasa neutra (nep). | |
| MA33676B1 (fr) | Compositions pharmaceutiques comprenant des dérivés de bisphosphonate et du cholécalciférol à dose élevée | |
| MX2010001047A (es) | Agente preventivo o agente terapéutico para enfermedades provocadas por metabolismo óseo anormal. | |
| CL2007003276A1 (es) | Metodo para administrar una cantidad eficaz de un agente activo de bisfosfonatos, mediante una via pulmonar; composicion farmaceutica que comprende a dichos bisfosfonatos; y kit farmaceutico que comprende a dichos bisfosfonatos. | |
| JP2006500401A5 (es) | ||
| BRPI0916808A2 (pt) | Composição pesticida, método para o controle de uma praga e método para melhorar os efeitos pesticidas de um composto de antranilamida ou de seu sal | |
| JP2010513328A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |